TY - JOUR T1 - Variation in mortality from pulmonary hypertension by aetiology JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA3788 VL - 46 IS - suppl 59 SP - PA3788 AU - Nesrin Mogulkoc AU - Tarik Simsek AU - Sanem Nalbantgil AU - Meral Kayikcioglu AU - Yasemin Kabasakal AU - Hakan Kultursay Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA3788.abstract N2 - Introduction: This study aims to establish the mortality rates of pulmonary hypertension (PH) patients treated at the Ege University Hospital PH Centre and to demonstrate the variation of mortality by aetiology.Methods: The study retrospectively and prospectively examined 167 adult PH patients undergoing right heart catheterisation between January 2008 and October 2014, reviewed and treated by a multidisciplinary team.Results: By Nice PH Classification, 115 of the patients were Group 1-PAH, 14 Group 3-ILD and 38 Group 4-CTEPH. Within Group 1, 33 (19.5%) were IPAH, 69 (40.8%) were CHD-APAH and 13 (7.7%) were CTD-APAH. Sixty-three patients (37.7% of the study group) have not survived the observation period. 85.7% of the ILD-PH group have died, compared to 27.5% of the CHD-APAH group. Taking group 1 IPAH group as a reference, the mortality risk of the CHD-APAH group was relatively low (HR=-0.40); however the risk was 4.54 times higher for the patients with ILD-PH (group 3). A significant difference has not been observed for other groups. As the WHO-FC category increased, risk increased by 3 to 4 times in comparison to WHO-FC II. One unit increase in cardiac index or DLCO (percent predicted) reduces the risk (HR=0.57, HR=0.97 respectively). BNP value higher than 150pg/mL and NT-proBNP value higher than 553pg/mL are determining factors for mortality (p=0.018, p=0.001 respectively).Conclusion: This study indicates that PH patient profiles and survival are different from European and American examples, CHD-APAH being the most prevalent patient population with better survival. ER -